A novel clinical therapy to combat infections caused by Hypervirulent Carbapenem-Resistant Klebsiella pneumoniae

We read with great interest on a recent study by Tao Lou and colleagues entitled “Risk factors for infection and mortality caused by carbapenem-resistant Klebsiella pneumoniae: A large multicentre case-control and cohort study” in this journal.1 Carbapenem-resistant K. pneumoniae (CRKP) has been increasingly reported in China reaching 21.9% of K. pneumoniae infections in hospitals according to CHINET (China Antimicrobial Surveillance Network) 2021 report (http://www.chinets.com).2 Data from this study showed a very high mortality rate caused by CRKP infections, reaching 24.2% for the 28-day crude mortality and over 45% for blood-stream infections.